Terms: = Leukemia AND CNTRL, CEP1, CEP110, 11064, ENSG00000119397 AND Treatment
4 results:
1. Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review.
Tan KW; Zhu YY; Qiu QC; Wang M; Shen HJ; Huang SM; Cao HY; Wan CL; Li YY; Dai HP; Xue SL
Ann Hematol; 2023 Sep; 102(9):2397-2402. PubMed ID: 37103615
[TBL] [Abstract] [Full Text] [Related]
2. Targeted therapy and disease monitoring in cntrl-FGFR1-driven leukaemia.
Brown LM; Bartolo RC; Davidson NM; Schmidt B; Brooks I; Challis J; Petrovic V; Khuong-Quang DA; Mechinaud F; Khaw SL; Majewski IJ; Oshlack A; Ekert PG
Pediatr Blood Cancer; 2019 Oct; 66(10):e27897. PubMed ID: 31250523
[TBL] [Abstract] [Full Text] [Related]
3. Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation and
Wehrli M; Oppliger Leibundgut E; Gattiker HH; Manz MG; Müller AM; Goede JS
Oncologist; 2017 Apr; 22(4):480-483. PubMed ID: 28242791
[TBL] [Abstract] [Full Text] [Related]
4. 8p11 myeloproliferative syndrome preceded by t(8;9)(p11;q33), cep110/FGFR1 fusion transcript: morphologic, molecular, and cytogenetic characterization of myeloid neoplasms associated with eosinophilia and FGFR1 abnormality.
Park TS; Song J; Kim JS; Yang WI; Song S; Kim SJ; Suh B; Choi JR
Cancer Genet Cytogenet; 2008 Mar; 181(2):93-9. PubMed ID: 18295660
[TBL] [Abstract] [Full Text] [Related]
